These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35455258)

  • 1. Adverse Events Following BNT162b2 mRNA COVID-19 Vaccine Immunization among Healthcare Workers in a Tertiary Hospital in Johor, Malaysia.
    Tan AY; Chang CT; Yu YK; Low YX; Razali NFM; Tey SY; Lee SWH
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following BNT162b2 mRNA COVID-19 vaccination among healthcare workers: A single-centre experience in Malaysia.
    Gan LL; Zahidah AR; Hazirah T; Nabilah HK; Aisyah Z; Amin INM; Ng DCE
    Med J Malaysia; 2022 May; 77(3):300-305. PubMed ID: 35638485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers.
    Lee DY; Kang DY; Kim E; Lee SJ; Baek JH; Lee JS; Park MY; Im JH
    Medicine (Baltimore); 2023 Mar; 102(11):e33236. PubMed ID: 36930126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers.
    Wi YM; Kim SH; Peck KR
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side effects among healthcare workers from a large Milan university hospital after second dose of BNT162b2 mRNA COVID-19 vaccine.
    Borroni E; Consonni D; Cugno M; Lombardi A; Mangioni D; Bono P; Oggioni M; Uceda Renteria S; Bordini L; Nava CD; Letzgus M; Gentiloni Silverj F; Castaldi S; Rognoni M; Cavallieri D'Oro L; Carugno M; Riboldi L; Ceriotti F; Bandera A; Gori A; Pesatori AC
    Med Lav; 2021 Dec; 112(6):477-485. PubMed ID: 34939617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.
    Jarynowski A; Semenov A; Kamiński M; Belik V
    J Med Internet Res; 2021 Nov; 23(11):e30529. PubMed ID: 34662291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host factors and history of SARS-CoV-2 infection impact the reactogenicity of BNT162b2 mRNA vaccine: results from a cross-sectional survey on 7,014 workers in healthcare.
    Ughi N; Del Gaudio F; Dicuonzo A; Orso M; Micheloni G; Puoti M; Pani A; Scaglione F; Zoppini L; Rossetti C; Epis OM; Bellavia G; Giroldi S; Moreno M; Bosio M
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7985-7996. PubMed ID: 34982462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
    Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.
    Shehab M; Alrashed F; Abdullah I; Alfadhli A; Ali H; Abu-Farha M; Channanath AM; Abubaker JA; Al-Mulla F
    Front Med (Lausanne); 2022; 9():881027. PubMed ID: 35755075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.
    Lim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim SH; Kim CK; Kim T; Choo EJ; Moon JE; Yun J; Park SK
    Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines.
    Dutta S; Kaur R; Charan J; Bhardwaj P; Ambwani SR; Babu S; Goyal JP; Haque M
    Cureus; 2022 Jan; 14(1):e21376. PubMed ID: 35198288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia.
    Almohaya AM; Qari F; Zubaidi GA; Alnajim N; Moustafa K; Alshabi MM; Alsubaie FM; Almutairi I; Alwazna Q; Al-Tawfiq JA; Barry M
    Prev Med Rep; 2021 Dec; 24():101595. PubMed ID: 34976653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
    Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
    Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers.
    Kadali RAK; Janagama R; Peruru S; Malayala SV
    Int J Infect Dis; 2021 May; 106():376-381. PubMed ID: 33866000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
    Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
    Front Immunol; 2021; 12():780594. PubMed ID: 34925359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.